Ligand Pharmaceuticals (LGND) to Release Quarterly Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Ligand Pharmaceuticals to post earnings of $1.46 per share and revenue of $55.5890 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals Price Performance

NASDAQ LGND opened at $189.94 on Thursday. The business’s fifty day moving average is $193.91 and its 200 day moving average is $183.36. Ligand Pharmaceuticals has a fifty-two week low of $93.58 and a fifty-two week high of $212.49. The company has a debt-to-equity ratio of 0.47, a quick ratio of 24.30 and a current ratio of 24.69. The company has a market capitalization of $3.74 billion, a PE ratio of 91.76 and a beta of 1.14.

Insider Buying and Selling at Ligand Pharmaceuticals

In other news, Director John W. Kozarich sold 467 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $195.91, for a total transaction of $91,489.97. Following the completion of the transaction, the director owned 43,187 shares in the company, valued at $8,460,765.17. This trade represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Octavio Espinoza sold 1,804 shares of Ligand Pharmaceuticals stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $188.31, for a total value of $339,711.24. Following the completion of the sale, the chief financial officer directly owned 26,186 shares in the company, valued at $4,931,085.66. This trade represents a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,205 shares of company stock valued at $611,192 over the last ninety days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Ligand Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Invesco Ltd. raised its holdings in shares of Ligand Pharmaceuticals by 64.6% during the 3rd quarter. Invesco Ltd. now owns 378,295 shares of the biotechnology company’s stock worth $67,011,000 after acquiring an additional 148,437 shares in the last quarter. Nomura Holdings Inc. purchased a new position in shares of Ligand Pharmaceuticals in the third quarter valued at $21,498,000. Bank of Montreal Can increased its position in Ligand Pharmaceuticals by 2,096.5% in the third quarter. Bank of Montreal Can now owns 125,769 shares of the biotechnology company’s stock worth $22,279,000 after purchasing an additional 120,043 shares during the last quarter. UBS Group AG raised its stake in Ligand Pharmaceuticals by 234.2% during the third quarter. UBS Group AG now owns 111,986 shares of the biotechnology company’s stock valued at $19,837,000 after purchasing an additional 78,476 shares in the last quarter. Finally, Castleark Management LLC purchased a new stake in Ligand Pharmaceuticals during the third quarter valued at $11,457,000. Institutional investors own 91.28% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LGND. Citigroup began coverage on Ligand Pharmaceuticals in a research report on Tuesday, December 9th. They set a “buy” rating and a $270.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Ligand Pharmaceuticals in a report on Monday, December 29th. HC Wainwright upped their price target on shares of Ligand Pharmaceuticals from $206.00 to $231.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Stifel Nicolaus raised their price objective on shares of Ligand Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Finally, Benchmark lifted their target price on shares of Ligand Pharmaceuticals from $175.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $239.33.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.